Evidence map›Paper›PMID 37123989›Full record

ArticleBiomedical engineering advances2023

Release Kinetics of Metronidazole from 3D Printed Silicone Scaffolds for Sustained Application to the Female Reproductive Tract.

Sydney E Herold, Anthony J Kyser, Margaret G Orr, Mohamed Y Mahmoud, Warren G Lewis, Amanda L Lewis, Jill M Steinbach-Rankins, Hermann B Frieboes

Open access · goldAbstract read
In one paragraph

Article in Biomedical engineering advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  4. Article
  5. Article
  6. Rising role of 3D-printing in delivery of therapeutics for infectious disease.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sydney E HeroldDepartment of Bioengineering, University of Louisville, Louisville, KY, USA.
Anthony J KyserDepartment of Bioengineering, University of Louisville, Louisville, KY, USA.
Margaret G OrrDepartment of Chemical Engineering, Bucknell University, Lewisburg, PA, USA.
Mohamed Y MahmoudDepartment of Bioengineering, University of Louisville, Louisville, KY, USA.
Warren G LewisDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, California USA.
Amanda L LewisDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, California USA.
Jill M Steinbach-RankinsDepartment of Bioengineering, University of Louisville, Louisville, KY, USA.
Hermann B FrieboesDepartment of Bioengineering, University of Louisville, Louisville, KY, USA.
University of Louisville · USUniversity of California San Diego · USBucknell University · US

Funding

ROLES OF SIALIDASE IN G. VAGINALIS-HOST INTERACTIONS DURING BACTERIAL VAGINOSISR01AI114635 · NIAID · WASHINGTON UNIVERSITY · PI LEWIS, AMANDA L., LEWIS, WARREN G · 2015 to 2025
$5.9M
3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosisR01AI168475 · NIAID · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN, LEWIS, AMANDA L. · 2022 to 2025
$3.0M
Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative Intravaginal Delivery Platforms to Treat Bacterial VaginosisR01AI139671 · NIAID · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN, LEWIS, AMANDA L. · 2019 to 2023
$2.5M
NIAID NIH HHS R01 AI114635NIAID NIH HHS R01 AI139671NIAID NIH HHS R01 AI168475
6 · The paper itself

Abstract

Sustained vaginal administration of antibiotics or probiotics has been proposed to improve treatment efficacy for bacterial vaginosis. 3D printing has shown promise for development of systems for local agent delivery. In contrast to oral ingestion, agent release kinetics can be fine-tuned by the 3D printing of specialized scaffold designs tailored for particular treatments while enhancing dosage effectiveness via localized sustained release. It has been challenging to establish scaffold properties as a function of fabrication parameters to obtain sustained release. In particular, the relationships between scaffold curing conditions, compressive strength, and drug release kinetics remain poorly understood. This study evaluates 3D printed scaffold formulation and feasibility to sustain the release of metronidazole, a commonly used antibiotic for BV. Cylindrical silicone scaffolds were printed and cured using three different conditions relevant to potential future incorporation of temperature-sensitive labile biologics. Compressive strength and drug release were monitored for 14d in simulated vaginal fluid to assess long-term effects of fabrication conditions on mechanical integrity and release kinetics. Scaffolds were mechanically evaluated to determine compressive and tensile strength, and elastic modulus. Release profiles were fitted to previous kinetic models to differentiate potential release mechanisms. The Higuchi, Korsmeyer-Peppas, and Peppas-Sahlin models best described the release, indicating similarity to release from insoluble or polymeric matrices. This study shows the feasibility of 3D printed silicone scaffolds to provide sustained metronidazole release over 14d, with compressive strength and drug release kinetics tuned by the fabrication parameters.

Indexed as

3D printed scaffoldsbacterial vaginosisdrug release kineticsMetronidazolesilicone scaffolds

Identifiers

PMID37123989
PMCPMC10136949
OpenAlexW4319786895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.